Biopharma AI
By
How Did Novartis’ 2025 Deals Shape Its Strategic Direction and What Might They Signal for 2026?
Novartis’ deal activity in 2025 reflected a deliberate and strategic effort to strengthen its scientific platforms, broaden its…
How Did AbbVie’s 2025 Deals Shape Its Year, and What Do They Signal for Growth in 2026?
NORTH CHICAGO, IL — As 2025 concludes, AbbVie Inc. reflects on a year of strategic dealmaking that complements…
Did AbbVie Successfully Manage 2025 Headwinds, and Are Rinvoq and Skyrizi Poised to Reach $31B+ Sales by 2027?
NORTH CHICAGO, ILLINOIS — As 2025 comes to a close, AbbVie reflects on a year marked by strong…
Pfizer’s Strategic Deals in 2025: Key Moves Shaping the Company’s Next Phase
Strategic Takeaways In 2025, Pfizer executed a series of focused and strategic deals aimed at strengthening its pipeline,…
Is AstraZeneca’s Acquisition of Modella AI at JPM 2026 a Signal That Pharma Is Internalizing AI for R&D?
Cambridge, U.K. | January 2026 AstraZeneca has taken a decisive step to deepen its artificial intelligence capabilities, announcing…
Is the $1 Billion Lilly–NVIDIA Alliance at JPM26 the Turning Point Where AI Becomes Industrial-Scale Drug Discovery?
San Francisco | January 12, 2026 The 44th Annual J.P. Morgan Healthcare Conference (JPM26) opened with a defining…
